6514 related articles for article (PubMed ID: 2738896)
21. Synthesis and antimetastatic properties of steroeoisomeric trycylic bis(dioxopiperazine) analogues in a B16 melanoma model.
Witiak DT; Trivedi BK; Campolito LB; Zwilling BS; Reiches NA
J Med Chem; 1981 Nov; 24(11):1329-32. PubMed ID: 7310809
[TBL] [Abstract][Full Text] [Related]
22. 1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity.
Shyam K; Hrubiec RT; Furubayashi R; Cosby LA; Sartorelli AC
J Med Chem; 1987 Nov; 30(11):2157-61. PubMed ID: 3669023
[TBL] [Abstract][Full Text] [Related]
23. Potential central nervous system antitumor agents. Aziridinylbenzoquinones.
Chou F; Khan AH; Driscoll JS
J Med Chem; 1976 Nov; 19(11):1302-8. PubMed ID: 1003407
[TBL] [Abstract][Full Text] [Related]
24. Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro.
Naylor MA; Swann E; Everett SA; Jaffar M; Nolan J; Robertson N; Lockyer SD; Patel KB; Dennis MF; Stratford MR; Wardman P; Adams GE; Moody CJ; Stratford IJ
J Med Chem; 1998 Jul; 41(15):2720-31. PubMed ID: 9667963
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
Anderson WK; Bhattacharjee D; Houston DM
J Med Chem; 1989 Jan; 32(1):119-27. PubMed ID: 2909723
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents.
Zhang SF; Earle J; MacDiarmid J; Bardos TJ
J Med Chem; 1988 Jun; 31(6):1240-4. PubMed ID: 3373492
[TBL] [Abstract][Full Text] [Related]
27. Antineoplastic agents. 1. Synthesis and antineoplastic activities of chloroethyl- and methylnitrosourea analogues of thymidine.
Lin TS; Fischer PH; Shiau GT; Prusoff WH
J Med Chem; 1978 Jan; 21(1):130-3. PubMed ID: 563461
[TBL] [Abstract][Full Text] [Related]
28. 1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity.
Shyam K; Furubayashi R; Hrubiec RT; Cosby LA; Sartorelli AC
J Med Chem; 1986 Jul; 29(7):1323-5. PubMed ID: 3806585
[TBL] [Abstract][Full Text] [Related]
29. Natural quinones as quinonemethide precursors--ideas in rational drug design.
Moore HW; Czerniak R; Hamdan A
Drugs Exp Clin Res; 1986; 12(6-7):475-94. PubMed ID: 3461932
[TBL] [Abstract][Full Text] [Related]
30. Potential bioreductive alkylating agents. 2. Antitumor effect and biochemical studies of naphthoquinone derivatives.
Lin AJ; Pardini RS; Cosby LA; Lillis BJ; Shansky CW; Sartorelli AC
J Med Chem; 1973 Nov; 16(11):1268-71. PubMed ID: 4147836
[No Abstract] [Full Text] [Related]
31. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
Workman P
Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
[TBL] [Abstract][Full Text] [Related]
32. Novel 1-haloalkyl-2-nitroimidazole bioreductive alkylating agents.
Heimbrook DC; Shyam K; Sartorelli AC
Anticancer Drug Des; 1988 Mar; 2(4):339-50. PubMed ID: 3130072
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and antitumor activity of preactivated isophosphamide analogues bearing modified alkylating functionalities.
Takamizawa A; Matsumoto S; Iwata T; Makino I; Yamaguchi K; Uchida N; Kasai H; Shiratori O; Takase S
J Med Chem; 1978 Feb; 21(2):208-14. PubMed ID: 621716
[TBL] [Abstract][Full Text] [Related]
34. New 2-substituted indoloquinone mitomycin analogues.
Iyengar BS; Remers WA; Catino JJ
J Med Chem; 1989 Aug; 32(8):1866-72. PubMed ID: 2754710
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.
Hay MP; Wilson WR; Moselen JW; Palmer BD; Denny WA
J Med Chem; 1994 Feb; 37(3):381-91. PubMed ID: 8308864
[TBL] [Abstract][Full Text] [Related]
36. Nitrobenzyl derivatives as bioreductive alkylating agents: evidence for the reductive formation of a reactive intermediate.
Kirkpatrick DL; Johnson KE; Sartorelli AC
J Med Chem; 1986 Oct; 29(10):2048-52. PubMed ID: 3761323
[TBL] [Abstract][Full Text] [Related]
37. Cytocidal action of the quinone group and its relationship to antitumor activity.
Begleiter A
Cancer Res; 1983 Feb; 43(2):481-4. PubMed ID: 6848172
[TBL] [Abstract][Full Text] [Related]
38. Narcotic alkylating agents: synthesis, structure and biological activities.
Frigola J; Colombo A; Mas J; Pares J
Farmaco Sci; 1988 Apr; 43(4):347-62. PubMed ID: 3203738
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA
J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.
Clement JJ; Gorman MS; Wodinsky I; Catane R; Johnson RK
Cancer Res; 1980 Nov; 40(11):4165-72. PubMed ID: 7471058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
